For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TQX865. CME/MOC/NCPD/AAPA credit will be available until January 27, 2026.
A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.1
2525 ratings
For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TQX865. CME/MOC/NCPD/AAPA credit will be available until January 27, 2026.
A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
5 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
27 Listeners
10 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
325 Listeners
2 Listeners
10 Listeners
2 Listeners
493 Listeners
280 Listeners
253 Listeners
3,332 Listeners
111,864 Listeners
56,221 Listeners
90 Listeners
1,095 Listeners
16,849 Listeners
519 Listeners
16,034 Listeners
349 Listeners
427 Listeners